Mar 21, 2019
RegeneRx Announces New Board Member
Feb 27, 2019
RegeneRx Closes $1.3 Million Convertible Debt Financing
Feb 12, 2019
RegeneRx's U.S. Joint Venture Initiates Key Phase 3 Dry Eye Clinical Trial with RGN-259
Jan 04, 2019
RegeneRx Update on Dry Eye and EB Clinical Trials
Oct 29, 2018
RegeneRx Partner Updates on Clinical Trials
Aug 02, 2018
RegeneRx Licensee GtreeBNT Enters into Joint Venture to Globally Develop RGN-137 for Treatment of Epidermolysis Bullosa
Jun 13, 2018
RegeneRx Holds Annual Meeting
May 29, 2018
RegeneRx Corrects Annual Meeting Date to Wednesday, June 13, 2018
Apr 09, 2018
RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome
Mar 14, 2018
RegeneRx Receives Notice of Allowance of U.S. Patent for Treatment of Corneal Wounds
Mar 12, 2018
RegeneRx Receives "Decision to Grant" European Patent For Treatment of Peripheral Neuropathy
Mar 02, 2018
RegeneRx Secures $1 Million in Funding
Feb 22, 2018
Key U.S. Dry Eye Patent Issued to RegeneRx
Feb 14, 2018
RegeneRx Receives Canadian Patent for Treating Neurological Injury and Damage
Dec 07, 2017
RegeneRx Releases Annual Letter to Shareholders
Sep 13, 2017
RegeneRx Receives Notice of Allowance for Key Dry Eye Patent in U.S.
Aug 31, 2017
RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia
Aug 30, 2017
RegeneRx Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York September 10-12, 2017
Aug 14, 2017
RegeneRx Collaborators Receive Notice of 'Intent to Grant' EU Patent for the Treatment of Peripheral Neuropathy
Jul 27, 2017
RegeneRx Updates on RGN-259 Phase 3 Dry Eye Trial